Adbiotech애드바이오텍
179530 · KOSDAQ · ₩179530 · 애드바이오텍
₩1,909▼ ₩74 (3.73%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩13B | ₩11B | ₩10B | ₩11B | ₩12B |
| Cost of sales | ₩7.7B | ₩7.1B | ₩7.3B | ₩7.5B | ₩6.8B |
| Gross profit | ₩5.1B | ₩4B | ₩3.2B | ₩3.1B | ₩5B |
| Operating income | −₩3.5B | −₩4.1B | −₩4.8B | −₩4.9B | −₩1.6B |
| Net income | −₩3.3B | −₩9B | −₩5.4B | ₩2.7B | −₩2.7B |
| Net income to shareholders | −₩3.3B | −₩8B | −₩2.9B | ₩2.7B | −₩2.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩48B | ₩23B | ₩28B | ₩31B | ₩21B |
| Current assets | ₩21B | ₩8.4B | ₩13B | ₩14B | ₩8.7B |
| Cash and equivalents | ₩3.9B | ₩639M | ₩3B | ₩1.2B | ₩1.2B |
| Total liabilities | ₩35B | ₩20B | ₩17B | ₩15B | ₩16B |
| Current liabilities | ₩31B | ₩15B | ₩13B | ₩12B | ₩13B |
| Borrowings | ₩17B | ₩11B | ₩13B | ₩13B | ₩13B |
| Total equity | ₩14B | ₩3B | ₩11B | ₩16B | ₩5.1B |
| Shareholders' equity | ₩15B | ₩4.8B | ₩13B | ₩16B | ₩5.1B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.3B | −₩4.1B | ₩315M | −₩8.6B | −₩2.2B |
| Capital spending | ₩378M | ₩193M | ₩240M | ₩727M | ₩3.6B |
| Free cash flow | −₩1.7B | −₩4.3B | ₩75M | −₩9.3B | −₩5.7B |
Consolidated where available. Amounts in won.
Also known as: Adbiotech / 애드바이오텍 / 179530 / KRX:179530
Source: KRX statistical information